NICE recommends anti-clotting drug Eliquis to patients

By Admin
A new anti-clotting drug manufactured by Pfizer and Bristol-Meyers Squibb has been recommended for use by the National Institute for Health and Clinica...

A new anti-clotting drug manufactured by Pfizer and Bristol-Meyers Squibb has been recommended for use by the National Institute for Health and Clinical Excellence (NICE).

Eliquis has been described by the organisation as a “clinically and cost-effective option for preventing blood clots.”

NICE believes that Eliquis, which is also known as apixaban, will be particularly suitable for use in post-operative patients who have just endured hip or knee surgery.

To read the latest edition of Healthcare Global, click here

According to NICE, for a course of treatment lasting 12 days following a knee replacement the cost of prescribing Eliquis will stand at approximately £41.16.

Other estimations suggest if the drug was prescribed to a patient for 34 days after a hip replacement the cost would be £116.62.

Professor Carole Longson, director of NICE's Health Technology Evaluation Centre, commented: "We are pleased to have been able to produce final draft guidance on the use of apixaban just six months after it received its license for the prevention of VTE in patients who have undergone planned hip and knee surgery."

She added: "The NICE clinical guideline 'Venous thromboembolism: reducing the risk' recommends that people having elective hip replacement or elective knee replacement surgery should be offered low-molecular-weight heparin, dabigatran etexilate, rivaroxaban, or fondaparinux to prevent VTE."

"Although apixaban had only been directly compared with one of the options recommended by the clinical guideline—enoxaparin, a low-molecular-weight heparin—the committee was satisfied that apixaban is a clinically and cost-effective option for preventing blood clots, alongside other effective treatments already recommended by NICE," Longson said.

Our magazine is now available on the iPad. Click here to download it.


Featured Articles

Honeywell comments on post-pandemic air quality challenges

Honeywell’s Sarah James calls for air sensors to ensure good air quality & Stefano D’Agostino explores how technology can help improve indoor air quality

Oracle's generative AI prioritises patient healthcare

Oracle's vision for better healthcare focuses on improving medical professionals quality time with patients, with Oracle Clinical Digital Assistant

2San's new app provides vital diagnostic product insights

2San’s leap forward in self diagnostics will bring ‘Better Care, Better Life’ to all, in a new step for 2San’s post-COVID-19 healthcare technology

Cylera’s Richard Staynings on healthcare cybersecurity

Technology & AI

Amazon Prime & One Medical to revolutionise healthcare

Digital Healthcare

Creating robust pharma supply chains with delivery devices

Medical Devices & Pharma